• Je něco špatně v tomto záznamu ?

NTRK Fusion Genes in Thyroid Carcinomas: Clinicopathological Characteristics and Their Impacts on Prognosis

B. Pekova, V. Sykorova, K. Mastnikova, E. Vaclavikova, J. Moravcova, P. Vlcek, P. Lastuvka, M. Taudy, R. Katra, P. Bavor, D. Kodetova, M. Chovanec, J. Drozenova, J. Astl, P. Hrabal, J. Vcelak, B. Bendlova

. 2021 ; 13 (8) : . [pub] 20210416

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21017946

Grantová podpora
NU21-01-00448 Ministerstvo Zdravotnictví Ceské Republiky
Institute of Endocrinology - EÚ, 00023761 Ministerstvo Zdravotnictví Ceské Republiky

Chromosomal rearrangements of NTRK genes are oncogenic driver mutations in thyroid cancer (TC). This study aimed to identify NTRK fusion-positive thyroid tumors and to correlate them with clinical and pathological data and determine their prognostic significance. The cohort consisted of 989 different TC samples. Based on the detected mutation, samples were triaged, and those that were positive for a BRAF, HRAS, KRAS, NRAS, RET, RET/PTC or PAX8/PPARγ mutation were excluded from further analyses. NTRK fusion gene testing was performed in 259 cases, including 126 cases using next-generation sequencing. NTRK fusion genes were detected in 57 of 846 (6.7%) papillary thyroid carcinomas and in 2 of 10 (20.0%) poorly differentiated thyroid carcinomas. A total of eight types of NTRK fusions were found, including ETV6/NTRK3, EML4/NTRK3, RBPMS/NTRK3, SQSTM1/NTRK3, TPM3/NTRK1, IRF2BP2/NTRK1, SQSTM1/NTRK1 and TPR/NTRK1.NTRK fusion-positive carcinomas were associated with the follicular growth pattern, chronic lymphocytic thyroiditis and lymph node metastases. NTRK1-rearranged carcinomas showed a higher frequency of multifocality and aggressivity than NTRK3-rearranged carcinomas. Tumor size, presence of metastases, positivity for the NTRK3 or NTRK1 fusion gene and a late mutation event (TERT or TP53 mutation) were determined as factors affecting patient prognosis. NTRK fusion genes are valuable diagnostic and prognostic markers.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21017946
003      
CZ-PrNML
005      
20241111144613.0
007      
ta
008      
210726s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers13081932 $2 doi
035    __
$a (PubMed)33923728
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Peková Bulanová, Barbora, $u Department of Molecular Endocrinology, Institute of Endocrinology, 11694 Prague, Czech Republic $d 1993- $7 xx0256338
245    10
$a NTRK Fusion Genes in Thyroid Carcinomas: Clinicopathological Characteristics and Their Impacts on Prognosis / $c B. Pekova, V. Sykorova, K. Mastnikova, E. Vaclavikova, J. Moravcova, P. Vlcek, P. Lastuvka, M. Taudy, R. Katra, P. Bavor, D. Kodetova, M. Chovanec, J. Drozenova, J. Astl, P. Hrabal, J. Vcelak, B. Bendlova
520    9_
$a Chromosomal rearrangements of NTRK genes are oncogenic driver mutations in thyroid cancer (TC). This study aimed to identify NTRK fusion-positive thyroid tumors and to correlate them with clinical and pathological data and determine their prognostic significance. The cohort consisted of 989 different TC samples. Based on the detected mutation, samples were triaged, and those that were positive for a BRAF, HRAS, KRAS, NRAS, RET, RET/PTC or PAX8/PPARγ mutation were excluded from further analyses. NTRK fusion gene testing was performed in 259 cases, including 126 cases using next-generation sequencing. NTRK fusion genes were detected in 57 of 846 (6.7%) papillary thyroid carcinomas and in 2 of 10 (20.0%) poorly differentiated thyroid carcinomas. A total of eight types of NTRK fusions were found, including ETV6/NTRK3, EML4/NTRK3, RBPMS/NTRK3, SQSTM1/NTRK3, TPM3/NTRK1, IRF2BP2/NTRK1, SQSTM1/NTRK1 and TPR/NTRK1.NTRK fusion-positive carcinomas were associated with the follicular growth pattern, chronic lymphocytic thyroiditis and lymph node metastases. NTRK1-rearranged carcinomas showed a higher frequency of multifocality and aggressivity than NTRK3-rearranged carcinomas. Tumor size, presence of metastases, positivity for the NTRK3 or NTRK1 fusion gene and a late mutation event (TERT or TP53 mutation) were determined as factors affecting patient prognosis. NTRK fusion genes are valuable diagnostic and prognostic markers.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Sykorova, Vlasta $u Department of Molecular Endocrinology, Institute of Endocrinology, 11694 Prague, Czech Republic
700    1_
$a Mastnikova, Karolina $u Department of Molecular Endocrinology, Institute of Endocrinology, 11694 Prague, Czech Republic
700    1_
$a Vaclavikova, Eliska $u Department of Molecular Endocrinology, Institute of Endocrinology, 11694 Prague, Czech Republic
700    1_
$a Moravcova, Jitka $u Department of Molecular Endocrinology, Institute of Endocrinology, 11694 Prague, Czech Republic
700    1_
$a Vlcek, Petr $u Department of Nuclear Medicine and Endocrinology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, 15006 Prague, Czech Republic
700    1_
$a Lastuvka, Petr $u Department of Otorhinolaryngology and Head and Neck Surgery, 1st Faculty of Medicine, Charles University and Motol University Hospital, 15006 Prague, Czech Republic
700    1_
$a Taudy, Milos $u Department of Otorhinolaryngology and Head and Neck Surgery, 1st Faculty of Medicine, Charles University and Motol University Hospital, 15006 Prague, Czech Republic
700    1_
$a Katra, Rami $u Department of Ear, Nose and Throat, 2nd Faculty of Medicine, Charles University and Motol University Hospital, 15006 Prague, Czech Republic
700    1_
$a Bavor, Petr $u Department of Surgery, 2nd Faculty of Medicine, Charles University and Motol University Hospital, 15006 Prague, Czech Republic
700    1_
$a Kodetova, Daniela $u Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University and Motol University Hospital, 15006 Prague, Czech Republic
700    1_
$a Chovanec, Martin $u Department of Otorhinolaryngology, Charles University, 3rd Faculty of Medicine, University Hospital Kralovske Vinohrady, 10034 Prague, Czech Republic
700    1_
$a Drozenova, Jana $u Department of Pathology, Charles University, 3rd Faculty of Medicine, University Hospital Kralovske Vinohrady, 10034 Prague, Czech Republic
700    1_
$a Astl, Jaromir $u Department of Otorhinolaryngology and Maxillofacial Surgery, Military University Hospital, 16902 Prague, Czech Republic
700    1_
$a Hrabal, Petr $u Department of Pathology, Military University Hospital, 16902 Prague, Czech Republic
700    1_
$a Vcelak, Josef $u Department of Molecular Endocrinology, Institute of Endocrinology, 11694 Prague, Czech Republic
700    1_
$a Bendlova, Bela $u Department of Molecular Endocrinology, Institute of Endocrinology, 11694 Prague, Czech Republic
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 13, č. 8 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33923728 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210726 $b ABA008
991    __
$a 20241111144611 $b ABA008
999    __
$a ind $b bmc $g 1676477 $s 1138388
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 13 $c 8 $e 20210416 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a NU21-01-00448 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a Institute of Endocrinology - EÚ, 00023761 $p Ministerstvo Zdravotnictví Ceské Republiky
LZP    __
$a Pubmed-20210726

Najít záznam

Citační ukazatele

Možnosti archivace